Literature DB >> 23542596

MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases.

Yong He1, Cheng Huang, Xiang Lin, Jun Li.   

Abstract

MicroRNAs (miRNAs) are a class of approximately 20-nucleotides single-stranded endogenous RNAs that regulate gene expression at the post-transcriptional level. miRNAs have recently been known to regulate cell proliferation, differentiation, and apoptosis. Fibrosis is the leading cause of organ dysfunction in diseases and results from an imbalance in the turnover of extracellular matrix components. Accumulating studies have demonstrated that miR-29 family participates in the development of liver fibrosis, renal fibrosis, pulmonary fibrosis, cardiac fibrosis. In this review, we are discussing the comprehensive role of miR-29 family in moderating profibrotic effect and its potential as therapeutic approach to fibrosis diseases.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23542596     DOI: 10.1016/j.biochi.2013.03.010

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  63 in total

Review 1.  From genetics to epigenetics: new insights into keloid scarring.

Authors:  Yongjing He; Zhenjun Deng; Mansour Alghamdi; Lechun Lu; Mark W Fear; Li He
Journal:  Cell Prolif       Date:  2017-01-05       Impact factor: 6.831

2.  Cardiac fibrosis and miR-433.

Authors:  Jae Gyun Oh; Roger J Hajjar; Woo Jin Park
Journal:  Ann Transl Med       Date:  2016-12

3.  MicroRNA-29b inhibits supernatants from silica-treated macrophages from inducing extracellular matrix synthesis in lung fibroblasts.

Authors:  Ximeng Lian; Xiaowei Chen; Jingping Sun; Guoliang An; Xiaoli Li; Yan Wang; Piye Niu; Zhonghui Zhu; Lin Tian
Journal:  Toxicol Res (Camb)       Date:  2017-08-24       Impact factor: 3.524

4.  Endothelial cell microRNA expression in human late-onset Fuchs' dystrophy.

Authors:  Mario Matthaei; Jianfei Hu; Laura Kallay; Charles G Eberhart; Claus Cursiefen; Jiang Qian; Eva-Maria Lackner; Albert S Jun
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-01-09       Impact factor: 4.799

5.  Emerging role of miRNAs in renal fibrosis.

Authors:  Youling Fan; Hongtao Chen; Zhenxing Huang; Hong Zheng; Jun Zhou
Journal:  RNA Biol       Date:  2019-09-24       Impact factor: 4.652

Review 6.  MicroRNA-29: A Crucial Player in Fibrotic Disease.

Authors:  Zhenjun Deng; Yongjing He; Xujuan Yang; Hang Shi; Ao Shi; Lechun Lu; Li He
Journal:  Mol Diagn Ther       Date:  2017-06       Impact factor: 4.074

7.  Post-transcriptional regulation in osteoblasts using localized delivery of miR-29a inhibitor from nanofibers to enhance extracellular matrix deposition.

Authors:  Eric N James; Anne M Delany; Lakshmi S Nair
Journal:  Acta Biomater       Date:  2014-05-09       Impact factor: 8.947

Review 8.  Role of the microRNA-29 family in myocardial fibrosis.

Authors:  Changyan Li; Nan Wang; Peng Rao; Limeiting Wang; Di Lu; Lin Sun
Journal:  J Physiol Biochem       Date:  2021-05-28       Impact factor: 4.158

Review 9.  Genetics, Epigenetics, and Genomics of Systemic Sclerosis.

Authors:  Gloria Salazar; Maureen D Mayes
Journal:  Rheum Dis Clin North Am       Date:  2015-05-20       Impact factor: 2.670

Review 10.  MicroRNA-29b regulation of abdominal aortic aneurysm development.

Authors:  Lars Maegdefessel; Junya Azuma; Philip S Tsao
Journal:  Trends Cardiovasc Med       Date:  2013-07-18       Impact factor: 6.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.